Owners

Our owners’ contribution to society

By supporting independent research at the highest level, our owners strive to significantly improve people’s health and well-being.

A stable ownership structure

Although traded on the NASDAQ Copenhagen (OMX: ALK B), ALK boasts an unusually stable ownership, with two shareholders having notified shareholdings of 5% or more.

The Lundbeck Foundation, one of Denmark’s largest enterprise foundations, is the controlling shareholder of ALK, holding 67% of the votes and 40% of the capital. The Foundation grants a minimum of DKK 500 million each year to public biomedical and health science research with a particular focus on neuroscience.

Its business activities encompass majority shareholdings in two other healthcare companies, H. Lundbeck and Falck, a significant shareholding in Ferrosan Medical Devices and Ellab, and an international portfolio of early-stage biotech companies, as well as management of a DKK 20+ billion portfolio of financial investments, primarily in listed securities.

Overview of the Lundbeck Foundation

ALK’s controlling shareholder

The Lundbeck Foundation is the largest and controlling shareholder of ALK, owning 40% of the capital and controlling 67% of the votes.

The Foundation’s commercial activities provide a financial stability that underpins its principal stated aim, that of funding research that aims to reduce the rising global burden of psychiatric and neurological diseases.